Nalbuphine HCL ER
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uremic Pruritus
Conditions
Uremic Pruritus
Trial Timeline
Apr 1, 2013 → Nov 1, 2013
NCT ID
NCT02373215About Nalbuphine HCL ER
Nalbuphine HCL ER is a phase 1 stage product being developed by Trevi Therapeutics for Uremic Pruritus. The current trial status is completed. This product is registered under clinical trial identifier NCT02373215. Target conditions include Uremic Pruritus.
What happened to similar drugs?
0 of 7 similar drugs in Uremic Pruritus were approved
Approved (0) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02174432 | Phase 2/3 | Completed |
| NCT02143973 | Phase 2/3 | Completed |
| NCT02373215 | Phase 1 | Completed |
Competing Products
15 competing products in Uremic Pruritus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 44 |
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 44 |
| Ravulizumab | AstraZeneca | Pre-clinical | 33 |
| Eculizumab | AstraZeneca | Phase 3 | 40 |
| Iptacopan | Novartis | Phase 3 | 44 |
| Iptcaopan 200 mg | Novartis | Phase 3 | 47 |
| Iptacopan | Novartis | Phase 3 | 47 |
| MR13A9 + Placebo | Kissei Pharmaceutical | Phase 3 | 40 |
| MR13A9 + Placebo | Kissei Pharmaceutical | Phase 2 | 35 |
| CCX168 | Amgen | Phase 2 | 27 |
| Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kg | Haisco Pharmaceutical Group | Phase 2 | 35 |
| Cemdisiran | Alnylam Pharmaceuticals | Phase 2 | 24 |
| cemdisiran + Placebos | Alnylam Pharmaceuticals | Phase 2 | 24 |
| nalbuphine HCl ER | Trevi Therapeutics | Phase 2/3 | 32 |
| nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BID | Trevi Therapeutics | Phase 2/3 | 32 |